Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

1.26
-0.0200-1.56%
Post-market: 1.280.0200+1.59%19:39 EST
Volume:3.36M
Turnover:4.29M
Market Cap:235.96M
PE:-4.88
High:1.31
Open:1.30
Low:1.25
Close:1.28
52wk High:6.77
52wk Low:1.09
Shares:187.27M
Float Shares:154.09M
Volume Ratio:0.94
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2583
EPS(LYR):-1.2551
ROE:-249.75%
ROA:-63.44%
PB:-49.67
PE(LYR):-1.00

Loading ...

BRIEF-Humacyte - On Nov 21, Co Delivered Notice To Jefferies Terminating Open Market Sale Agreement Entered On Sept 1, 2022

Reuters
·
Nov 27

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 20

Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)

TIPRANKS
·
Nov 14

Humacyte Is Maintained at Buy by Benchmark

Dow Jones
·
Nov 14

Humacyte (HUMA): Reassessing Valuation Following Strong Phase 3 Results, New Launches, and IP Wins

Simply Wall St.
·
Nov 14

Biotech Humacyte's Q3 net income beats expectations as Symvess sales rise

Reuters
·
Nov 12

Humacyte Q3 EPS $(0.11) Beats $(0.16) Estimate, Sales $753.000K Miss $922.333K Estimate

Benzinga
·
Nov 12

BRIEF-Humacyte Q3 Operating Expenses USD 25.143 Million

Reuters
·
Nov 12

Could Humacyte's (HUMA) High-Risk Patient Focus Redefine Its Competitive Edge in Biotech?

Simply Wall St.
·
Nov 12

Top News Today: Stocks Mostly Higher on Government Reopening Hopes

Dow Jones
·
Nov 12

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 11

Humacyte announces presentation of two-year results from V007 Phase 3 trial

TIPRANKS
·
Nov 10

Humacyte Reports Positive Two-Year Results for Bioengineered Vessel in Dialysis Access Trial

Reuters
·
Nov 10

Humacyte Announces Presentation of Positive Two-Year Results From Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025

THOMSON REUTERS
·
Nov 10

BRIEF-Humacyte To Present Third Quarter Financial Results And Provide Business Update On November 12, 2025

Reuters
·
Nov 06

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

THOMSON REUTERS
·
Nov 06

Humacyte Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
Nov 04

Humacyte’s Phase 3 Trial: A New Era for Renal Disease Treatment?

TIPRANKS
·
Oct 28

Humacyte Announces $60 Million Registered Direct Offering of Common Stock and Warrants

Reuters
·
Oct 14

Humacyte Is Maintained at Buy by BTIG

Dow Jones
·
Oct 13